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ABSTRACT 
An overwhelming volume of evidence has emerged on the estrogen-like 
effects of many chemicals released into the environment. Because 
environmental estrogenic pollutants can jeopardize the continuation of affected 
life forms by disrupting reproduction, concern has focussed on the impact of such 
compounds on human and wildlife health. We have developed a bioassay for 
determining estrogenicity of compounds that can serve as a sensitive biomarker 
of estrogenicity in serum from humans and wildlife. This assay depends upon 
the measurement of two plasma proteins, angiotensinogen and ceruloplasmin, 
which are synthesized in the liver. The assay is minimally invasive, requiring 
only 500 J.l1 of serum. We have shown that estrogenic compounds upregulate 
mRNA synthesis for angiotensinogen and ceruloplasmin in cultured human liver 
cells. Furthermore, when ethinyl estradiol or diethylstilbestrol were administered 
to adult ovariectomized female rats, enhanced serum levels of angiotensinogen 
and ceruloplasmin correlated with increased weight of the uterus. We conclude 
that this non-invasive bioassay may be used in place of the classic uterotrophic 
assay, which requires ovariectomy prior to treatment with the test substance and 
death of the test animal at the time of analysis. We recommend that 
angiotensinogen, ceruloplasmin, and/or other estrogen regulated plasma proteins 
synthesized by the liver and immediately secreted into plasma can be used as 
effective, minimally invasive biomarkers for estrogenicity in humans and wildlife. 
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EXECUTIVE SUMMARY 
A. Study Purpose 
A remarkable diversity of chemically different environmental agents have been 
shown to mimic the biological effects of estrogen. Estrogenic contaminants are found in 
waste streams and in hazardous waste dumps across the country. In some cases, 
these environmental compounds may be potent estrogens which have been used for 
their hormonal activity (e.g diethylstilbestrol, DES), or in other cases, they are weak 
estrogens in which hormonal activity is an inadvertent function (e.g. bisphenol A). 
Additionally, the wide distribution of weakly estrogenic flavonoid pigments in food crops 
(e.g. genistein in soy) and medicinal plants raises additional questions about the 
possible health risks and benefits of these compounds, meriting closer examination of 
their presence in the human diet. (Regardless of their origin, pollution by estrogenic 
compounds can be devastating, in that they will disrupt reproduction and therefore 
jeopardize the continuation of affected life forms). 
While most of these environmental contaminants elicit estrogenic effects, their 
biological actions are usually 1000 times less active than 17J3-estradiol. This suggests 
that weak environmental estrogens may be without physiological consequence. 
However, estrogenic compounds warrant concern because most of these environmental 
contaminants are lipid-soluble and ubiquitous, and therefore can accumulate in the food 
chain. Also, since these contaminants mostly exist as mixtures in the environment, the 
additivity of adverse effects of the various contaminants could reach a threshold for 
toxicity even when the separate components are not in sufficient quantity to be readily 
identified in environmental samples. Thus, a relatively quick and reliable bioassay that 
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could detect the estrogenicity of environmental compounds is needed. Furthermore, a 
bioassay is needed whose endpoints could be used as biomarkers for environmental 
exposure to estrogenic substances. Here we propose such an assay. 
Most studies on the estrogenic activity of compounds have been performed using 
an assay that targets the uterus. In the classic uterotropic assay in rodents, estrogens 
caused an increase in uterine weight, fluid retention and cell proliferation. However, 
estrogens affect many other organs such as the liver. Hepatic estrogen receptors 
mediate estrogenic effects on mammalian liver metabolism and are thereby involved in 
the regulation of important physiological and pathological processes, such as 
coagulation, atherosclerosis, and hypertension. Indeed, estrogens have been shown to 
upregulate a number of proteins that are produced in the liver, including ceruloplasmin 
(CPN) and angiotensinogen (ANGI). CPN and ANGI are secreted into the plasma 
where their concentrations increase directly in response to estrogens. Therefore, we 
decided to determine if plasma CPN and ANGI levels could be used as. endpoints in a 
bioassay of estrogenic compounds in test animals and as reliable biomarkers of 
estrogen exposure both in wildlife and humans. 
The concomitant use of two proteins as biomarkers significantly decreases the 
risk of misinterpretation due to non-specific upregulation unavoidably linked with single 
endpoint bioassays. In the uterine weight assay, lack of specificity for estrogenicity is a. 
serious confounding effect, since uterine weight increases in response to many non­
estrogenic compounds. Admittedly, CPN synthesis is also upregulated by many non­
estrogenic agents including copper, indomethacin and phenytoin. Likewise, ANGI 
responds to increased plasma sodium chloride (NaCI), isoproterenol, and guanfacine. 
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However, the only known common pathway of induction for these two proteins is a 
response to estrogen stimulation. 
Another advantage of using the liver in the assessment of estrogenic activity is 
that the majority of estrogenic compounds, both endogenous and exogenous, are 
usually metabolized in the liver before they reach their target organ. In some cases, 
inactive parent compounds (proestrogens) are converted to active estrogens and in 
other cases, potent estrogens are inactivated. In either case, metabolism may result in 
chemically reactive intermediates which may yield unexpected toxicities. Many 
estrogenic products of bioactivation are relatively short-lived. Therefore, bioactivated 
proestrogens could affect the surrounding tissue (ie, the liver), but not reach sufficiently 
high levels systemically to effect an estrogenic response at the uterus. 
B. Hypotheses 
The underlying hypothesis of this research is that the liver, being the organ most 
exposed to ingested chemicals and the tissue..in which bioactivation is greatest, is the 
most responsive target organ following exposure to estrogenic and proestrogenic 
environmental contaminants. Therefore, a bioassay based on the upregulation of well 
characterized proteins synthesized by the liver would be an improvement over the 
current measure of uterine wet weight because the endpoints are more sensitive and 
specific. The endpoints can be assessed repeatedly while yielding a quantitative 
response. Finally, the assay readily lends itself to transformation into a minimally 
invasive biomarker assay for wildlife and humans exposed to estrogens. Estrogenic 
and proestrogenic environmental contaminants should upregulate CPN and ANGI 
expression and synthesis in the liver and their concentration in the serum affording a 
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ready measure of estrogenicity. The objectives of this project are to developm a reliable 
and sensitive bioassay to detect estrogenic and proestrogenic environmental 
contaminants, and to develop sensitive biomarkers of exposure to estrogenic and 
proestrogenic environmental contaminants suitable for use in wildlife and humans. 
C.	 TASKS: 
1.	 Confirmation of the estrogenic response of ceruloplasmin and 
angiotensinogen. 
Estrogens, and compounds with estrogenic activity, are thought to produce their 
effects by combining with specific estrogen receptors (ERs) present in target cells. 
Binding of the ligand-receptor complex to the estrogen response element (ERE) initiates 
changes in transcription which eventually lead to estrogenic effects in target tissues. To 
confirm the well-documented effects of estrogen on the expression and synthesis of 
ANGI and CPN and to confirm that estrogens regulate ANGI and CPN transcription 
directly, messanger"'ribonucleic acid (mRNA) levels of these two proteins were 
measured in vitro using HepG2 cells. The HepG2 cell line is an established human liver 
cell line commonly used for the study of estrogenic effects. It stably expresses the ER 
and the proteins of interest, ANGI and CPN. 
HepG2 cells were cultured with or without 10-6 M diethylstilbestrol (DES) for 0, 6 
or 48 hr. For each time point, mRNA concentrations of ANGI and CPN were measured 
from the cells. Northern blot analysis with complementary deoxyribonucleic acid 
radiolabeled phosphorus (32p-cDNA) ANGI and CPN probes showed that treatment of 
cells with DES for 48 hours resulted in a significant (P<0.05) increase in CPN mRNA 
levels. However, ANGllevels, while increased at 6 hrs, had returned to control levels by 
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48 hours. These results confirmed that estrogen-dependent increases in serum levels 
of CPN and ANGI are associated with DNA-directed events. 
2.	 Establishment of methods. 
a.	 Establishing methods for measuring
 
ceruloplasmin (CPN).
 
CPN in a copper-binding protein made in the liver and immediately excreted into 
plasma. CPN levels can be determined using a number of different techniques, two of 
which were evaluated during this study. First, a sandwich enzyme-linked immunoassay 
(ELISA) was developed; however, preliminary work on measuring CPN using an ELISA 
yielded mixed results. While the ELISA worked well for measuring CPN in human 
plasma, this success was not extended to rat plasma. The problem was determined to 
be due to a lack of specificity of one of the antibodies which resulted in extensive non­
specific binding. Subsequently, an enzymatic assay that depended upon the oxidase 
activity of CPN was evaluated. 
To examine the ability of this assay to measure CPN in rat plasma and to detect 
treatment-induced differences in CER, ovariectomized female rats were treated with 
daily subcutaneous injections of 0.05 mg/kg body weight of DES (in corn oil) or corn oil 
only for 14 days. Plasma samples were collected 7 and 15 days after the initiation of 
treatment. Results indicate that this assay was able to measure CER in rat and human 
plasma. Additionally, it was shown that this assay could detect estrogen-induced 
increases in CER. Significant increases (P<0.05) in CER were seen after 14 days of 
treatment with DES. 
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b. Establishing method for measuring angiotensinogen (ANGI). 
ANGI is an a,2-globulin glycoprotein that is mainly synthesized by the liver and 
secreted into the bloodstream. Angiotensinogen is usually determined in plasma with a 
radioimmunoassay (RIA). Prior to the RIA, ANGI is converted to angiotensin I, a small 
decapeptide, in the presence of the enzyme renin (ANGI-----renin----->Angiotensin I). 
The radioimmunoassay measures the angiotensin I (AI) generated during this reaction. 
Commercially available RIA kits are designed for measuring renin activity in human 
plasma, thus modifications of these kits are necessary for their use in measuring 
plasma ANGI levels in rats. 
Preliminary work with 1.25 I1g renin indicated that higher than expected levels of 
angiotensin I were present at time zero in the rat plasma. Additionally, after extending 
the length of incubation, no further increase in angiotensin I levels were seen therefore 
indicating no conversion from ANGI. To determine if there was time zero conversion 
due to the use of too much renin, smaller amounts of renin (0 to 1.25x1 0-5 I1g) were 
used. Results indicated that the use of smaller amounts of renin resulted in lower levels 
of angiotensin I at time zero and that under these conditions, increasing the length of 
incubation with renin led to increasing angiotensin I formation. These data indicated 
ANGI was being converted to angiotensin I and could be detected in the plasma 
samples. All further experiments were carried out with no renin in the time zero 
samples and as expected, reproducible ANGI values could then be determined. 
3. Validation of the bioassay. 
The first task demonstrated unequivocally that DES upregulates ANGI and CPN 
transcriptionally. The second tasks indicated that reliable methods had been 
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established to measure ANGI and CPN in rat plasma. In task 3, we validated our 
bioassay in vivo. Additionally, to further support the use of our bioasay in determining 
the estrogenicity of compounds, ANGI and CPN upregulation were evaluated against 
the current gold standard, by measuring the uterine weight in these animals. 
Thus, ovariectomized female rats were treated with repeated daily injections of 
DES (0.05 mg/kg) or vehicle (corn oil) subcutaneouslu (sc) daily for 14 days. Animals 
were killed 24 hr after the adm inistration of the last dose (on days 8 and 15). Animals 
were first anesthetized with pentobarbital and blood collected by cardiac puncture. 
Plasma was separated by centrifugation and stored at -70°C prior to assay for ANGI 
and CPN concentrations. Animals were then euthanized by cervical dislocation. The 
livers were excised, wet weighed, and sectioned into approximately 1 g slices and 
stored in liquid nitrogen for later use. The uteri were also excised, cleaned and 
weighed. 
Examination of the data indicates the bioassay performed as expected fo.Hawing 
treatment with DES. Significant increases (P<O.05) in ANGI and CPN were seen 
following exposure. Additionally, these increases correlated with increases in uterine 
weight. 
D.	 CONCLUSIONS 
1.	 Increased angiotensinogen and ceruloplasmin levels in response to estrogen 
treatment are DNA-directed events involving transcriptional activation. This is 
supported by the results that exposure of HepG2 cells to DES (1x10-6 M) caused 
a significant increase in angiotensinogen mRNA expression at 6 hours and 
ceruloplasmin mRNA expression at 48 hours. 
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2.	 Liver-derived plasma proteins can be used as a bioassay for determiningthe 
estrogenicity of compounds. This is based on the fact that increased levels of 
angiotensinogen and ceruloplasmin were seen in response to treatment with 
DES. 
3.	 Liver-derived plasma proteins can also be used as biomarkers of exposureto 
estrogenic compounds. This is based on the fact that one could obtain plasma 
with increased levels of ceruloplasmn and angiotensinogen. following treatment 
with DES, without requiring sacrifice of the animal. 
E.	 RECOMMENDATIONS 
1.	 This non-invasive bioassay may be used in place of the classic uterotrophic 
assay. 
2.	 Angiotensinogen, ceruloplasmin, and/or other estrogen-regulated plasma 
proteins synthesized in the liver, and immediately secreted into plasma, should 
be investigated as possible biomarkers of estrogen exposure in humans and 
wildlife. 
xvii 
Chapter 1. INTRODUCTION 
A.	 Environmental Estrogens 
Environmental estrogenic pollution has gained enormous attention in the last 
half-century in the United States, as well as abroad. Indeed, a large number of 
chemically diverse environmental contaminants have been shown to have estrogen-like 
effects. Examples of environmental estrogens include the pesticides kepone 
(Hammond et aI., 1979), methoxychlor (Bulger et aI., 1985; Tullner 1961) and o,p'-DDT 
(Ceciletal., 1971; Doddsetal., 1938; Roorycketal., 1987; Robisonetal., 1984; 
Singhal et aI., 1970; Welch et aI., 1969), polychlorinated biphenyls (PCBs; Korach et 
aI., 1988; Jansen et aI., 1993), bisphenol A (a breakdown product of plastics; Ashby 
and Tinwe1l1998; Krishnan et aI., 1993), zearalenone (a fungal product; Sheehan et aI., 
1984), alkylphenolic compounds (Soto et aI., 1991; White et at., 1994); and 
phytoestrogens produced by a variety of plants (Cheng et aI., 1953; Dees et at., 1997; 
Zava et aI., 1997). Figure 1 shows the structure of some common estrogenic and 
estrogen-like compounds. 
In some cases, these xenoestrogens may be potent estrogens which have been 
specifically developed for their hormonal activity (e.g. DES), while in other cases, they 
are weak estrogens found to exert hormonal activity as an unexpected side effect (e.g. 
DDT). Additionally, the wide distribution of weakly estrogenic flavonoid pigments in 
food crops (e.g. genistein in soy) and medicinal plants raises additional questions about 
the possible health benefits and risks of these compounds. 
1 
OH
 
H 
17f3-Estradiol 
H 
>---OH 
Diethylstilbestrol 
CI'-----< 
CCI3 
o,p'-DDT 
Figure 1. Structure of estrogen and some estrogen-like compounds. 
While most of these environmental contaminants elicit estrogenic effects, their 
biological actions are usually 1000 times less active than estradiol (Nelson 1974; 
Korach et aI., 1978; Korach et aI., 1"988). This tends to suggest that weak 
environmental estrogens might be without physiological consequence. However, 
estrogenic compounds warrant concern because most of these environmental 
contaminants are lipid-soluble and ubiquitous, and can accumulate in the food chain. 
Also, since these contaminants mostly exist as mixtures in the environment, the 
additivity of adverse effects of the various contaminants could reach a threshold for 
toxicity even when the separate components are not in sufficient quantity to be toxic or 
even readily measured in environmental samples. 
B.	 Health Effects of Environmental Estrogens 
Evidence of deleterious estrogenic effects in humans from xenoestrogens comes 
from studies of young boys and girls living in industrial countries. Prepubertal breast 
development was observed in young boys and girls, and the young girls started 
menarche much earlier than expected (Perez-Comas 1982). Additionally, estrogenic 
compounds have been linked with hepatocellular, cervical, testicular, ovarian, and 
breast cancers in experimental animals (Preat et aI., 1986; Watanabe and Kobayashi 
1993) and humans (Christopherson et aI., 1977; Herbst et aI., 1971; Yager et aI., 1991). 
However, increased incidence of cancers is not the only health effects seen with 
estrogenic compounds. In 1947, crop dusters handling DDT had decreased sperm 
counts (Singer 1949) and workers in a kepone plant suffered low sperm counts, 
impotence, and loss of libido (Guzelian 1982). These effects have been confirmed in 
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laboratory animal studies. DES and 4-octylphenol, a phthalate plasticizer, caused a 
decrease in testicular size and sperm production in rats (Sharpe et aI., 1995). In 
addition, reproductive changes such as infertility and male feminization in wild species 
have been attributed to environmental estrogens. Adverse effects have been seen in a 
variety of wild and domestic species including fish (Jobling et aI., 1996), cheetahs 
(Setchell et aI., 1987), quail (Leopold et aI., 1976), and alligators (Guillette et aI., 1994). 
Without a doubt, environmental estrogens have the potential to cause serious 
adverse effects that disrupt reproduction and threaten species survival. Assessment of 
the estrogenicity of chemicals is needed to make judicious waste management 
decisions. Furthermore, no methods exist to determine whether people are exposed to 
effective doses. Thus, a bioassay is needed, whose endpoints can be used as 
biomarkers of environmental exposure to estrogenic substances. Here we propose 
such an assay. 
c.	 Need for Bioassay/Biomarkers 
Most studies on the estrogenic activity of compounds have been performed 
using a bioassay that focuses on the uterus. In the classic uterotrophic assay in 
rodents, estrogens cause an increase in uterine weight, fluid retention and cell 
proliferation (Dodds et aI., 1938; Welch et aI., 1969). Although the uterotrophic 
response assay is widely used for identifying estrogenic compounds, hypertrophy and 
hyperplasia of the uterus can be induced aspecifically by non-estrogenic compounds 
including corticosteroids and antiestrogens. Moreover, the precision of the test is 
affected by surgical techniques (e.g. bleeding of the animal) and the variability of 
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uterine weight due to nutritional status and estrus cycling. Furthermore, uterine weight 
cannot be used as a biomarker in wildlife or humans, since this endpoint requires 
sacrifice of the exposed subject. Finally, uterine weight is gender-specific which 
renders half the population unavailable for assessment of exposure. Therefore, while 
this bioassay has its advantages for use, the fact that it requires sacrifice of the animal 
precludes its useless as a nonlethal biomarker of estrogen exposure. These limitations 
have caused some researchers to begin looking at other target organs for estrogenic 
effects. An area that has been gaining a lot of attention involves assessing the hepatic 
effect of estrogens. 
D.	 Use of liver proteins as a bioassay and as biomarkers of exposure to 
estrogenic compounds 
Several in vivo studies have demonstrated a direct relationship between 
estrogen levels and the production of several liver plasma proteins (Kendall and Rose 
1992; Klett et aI., 1992; Kneifel and Katzenellenbogen 1981; Middleton and Linder 
1993; Sunderman et aI., 1971). We have developed a bioassay based on the 
demonstrated response of the liver to estrogenic compounds. This method is based on 
the estrogenic upregulation of the hepatic production of the two plasma proteins, 
ceruloplasmin (CPN) and angiotensinogen (ANGI). These two proteins have been 
shown to be predominantly synthesized in the liver and to be upregulated by estrogens 
in both sexes in experimental animals and humans (Hongbrown and Deschepper 1993; 
Middleton and Linder 1993; Kneifel and Katzenellenbogen 1981; Sunderman et aI., 
1971). Because neither protein is stored in the liver, but secreted immediately upon 
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synthesis, non-specific necrotizing hepatotoxic compounds will not increase their 
plasma levels. As a result, our method could serve as a bioassay, and yield proteins 
that could serve as biomarkers to effectively identify exposure to estrogenic 
substances. 
1. Ceruloplasmin 
Ceruloplasmin functions in the transport of copper. It is produced in the liver and 
immediately secreted into the systemic circulation. Several studies have established 
that CPN levels increase following exposure to estrogens in both humans and 
laboratory animals. In fact, because CPN is a liver-derived plasma protein, increases in 
its levels have helped in establishing the liver as a target organ of estrogens. 
The possibility that estrogens caused increased levels of CPN began to surface 
in the mid 1950s. It was noted that rats treated with estrogens had increased levels of 
copper and that this increased copper level was attributable to increa~sed levels of CPN 
(Meyer et aI., 1958; Turpin et aI., 1952). Studies in rats treated with DES, estradiol, or 
ethinyl estradiol (EE) have all shown increases in both serum and mRNA levels of CPN 
(Clemente et aI., 1992; Kendall and Rose 1992; Middleton and Linder 1993; Musa et 
aI., 1965; Sunderman et aI., 1971). Additionally, it was also noted that increased levels 
of CPN were observed in humans exposed to estrogenic compounds; specifically in 
women who were taking oral contraceptives (Carruthers et aI., 1966; Musa et aI., 1965) 
or who were receiving estrogen replacement therapy (Clemente et aI., 1992). 
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2. Angiotensinogen 
Angiotensinogen is a glycoprotein that is mainly synthesized by the liver and 
secreted into the bloodstream. It is a central component of the renin-angiotensin 
system (RAS) and serves as the sole substrate for renin in its generation of angiotensin 
I which is then converted to angiotensin II, a potent vasoconstrictor. 
The ability of estrogens to increase levels of ANGI has been well documented. 
Studies examining the correlation between estrogen exposure and increased levels of 
ANGI have been reported since the late 1930s (Dodds et aI., 1938). Treatment with 
DES, estradiol or EE has been shown to result in a positive correlation between 
exposure and increased levels of ANGI protein and mRNA in laboratory animals 
(Gontar et aI., 1984; Gordon et aI., 1992; Helmer and Griffith 1952; Klett et aI., 1992; 
Kneifel and Katzenellenbogen 1981). Similar increases have also seen in humans 
(Schunkert et aI., 1997). 
3. Proposed Bioassay/Biomarkers 
These previous studies confirm the liver as a target organ for estrogenic 
compounds. Therefore, since CPN and ANGI are secreted directly into the plasma 
where their concentrations increase directly in response to estrogens, they should 
serve as excellent endpoints for a bioassay in test animals and reliable biomarkers both 
in wildlife and humans. Moreover, the regulatory region of the ANGI gene has been 
reported to contain a functional estrogen responsive element, stressing the link 
between the expression of this protein and a direct estrogenic action (Feldmer et aI., 
1991 ). 
7 
The concomitant use of two proteins as biomarkers significantly decreases the 
risk of misinterpretation of the data which can occur due to non-specific upregulation 
which is unavoidably linked with single endpoint bioassays. If' the uterine weight 
assay, lack of specificity for estrogenicity is a serious confounding effect, since uterine 
weight increases in response to many nonestrogenic compounds. Admittedly, CPN 
synthesis is also upregulated by many non-estrogenic agents including copper, 
indomethacin and phenytoin. Likewise, ANGI responds to increased plasma NaCI, 
isoproterenol, and guanfacine. However, the only known common pathway of induction 
for these two proteins is a response to estrogen stimulation. 
Another advantage of using the liver in the assessment of estrogenic activity is 
because the majority of compounds, both endogenous and exogenous, are usually 
metabolized in the liver before they reach their target organ. In some cases weakly 
estrogenic corppounds (proestrogens) are converted to more active estrogens and in 
other cases, potent estrogens are inactivated. In either case, metabolism may result in 
chemically reactive intermediates which may yield unexpected toxicities. Many 
estrogenic products of bioactivation are relatively short-lived. Therefore, bioactivated 
proestrogens could affect the surrounding tissue (i.e. the liver), but not reach sufficiently 
high levels systemically to effect an estrogenic response at the uterus. 
The importance of liver exposure to environmental estrogens is underscored by 
convincing experimental data. DDT produces predominantly or exclusively liver cancers 
in rodents (Preat et aI., 1986) while PCBs show liver tumor enhancing properties 
(Cogliano 1998; Yager and Shi 1991). Furthermore, in humans, the administration of 
estrogenic compounds in oral contraceptives has led to the occurrence of liver tumors 
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(Christopherson et aI., 1977; Yager and Shi 1991). Ingestion is the most common route 
of exposure to environmental pollutants, and the portal system shunts all compounds 
absorbed from the intestine directly.to the liver. Thus, we hypothesized that changes 
occurring in the liver may be earlier and more sensitive indicators of the estrogenicity of 
environmental contaminants than the uterus. 
9 
Chapter 2. METHOD DEVELOPMENT 
A.	 mRNA Detection Using cDNA probes 
The overall objective of this project was to exam ine whether increased levels of 
two liver-derived plasma proteins, ceruloplasmin and angiotensinogen, could be used 
as a biomarker of exposure to environmental estrogen. While increases in protein 
levels can be explained by a number phenomena, DNA-directed events cause 
increased mRNA levels and increased protein levels. We used an in vitro assay to 
confirm that increased levels of ceruloplasmin and angiotensinogen in response to 
estrogens are mediated through DNA-directed events. This assay employing molecular 
biology techniques to detect ceruloplasmin and angiotensinogen mRNA levels. In order 
to mimic the in vivo system as closely as possible, we used a human liver cancer cell 
line (HepG2) that has been shown to maintain the ability to produce several of the liver 
proteins that are destined for the plasma. The mRNA levels of CPN and ANGI was 
used to correlate with the pattern of protein expression seen in the in vivo system. 
1.	 Materials and Methods 
a. HepG2 Cell Culture. 
The HepG2 cell line is derived from a human hepatocarcinoma and is commonly 
used to study the effects of estrogens (Tam et aI., 1985; Coezy et aI., 1987). This cell 
line has been shown to stably express the estrogen receptor (Koschinsky et aI., 1986) 
and retain many of the differentiated characteristics of normal hepatocytes, including 
the ability to synthesize many serum proteins including ceruloplasmin (Knowles et aI., 
10 
1980) and angiotensinogen (Koschinsky et aI., 1986). Cells were cultured in 75 cm 2 
flasks in RPMI1640 medium supplemented with 5°k bovine serum, 0.6 mg/ml insulin, 
100 units penicillin/ml and 100 Jlg streptomycin/ml. Cells were maintained at 37°C in 
humidified atmosphere of 95% air and 5°k CO2 . The medium was changed three times 
a week and cells subcultured weekly after trypsinization (0.05% trypsin in Hank's 
buffered salt solution (HBSS). 
b. Probe Propagation and Preparation. 
i. Angiotensinogen eDNA 
Human angiotensinogen eDNA was donated by Dr. C. Jerome (College de 
France) in plasmids containing promoters (T7 and Sp6) that could be utilized in 
riboprobe synthesis. The eDNA (1.69 kb) was inserted in the Hind III/Xba I restriction 
site of a plasmi"d which contained an ampicillin-resistance gene. To propagate and 
multiply the plasmid, E. Coli competent cells (DH5a) were transformed with the plasmid 
and grown on agar plates containing ampicillin. Amplification of the eDNA insert was 
obtained via large-scale growth of the transformed E. Coli cells, and separation of the 
plasmid from the E. Coli cells via alkaline lysis, followed by purification of the plasmid 
via cesium chloride centrifugation. The orientation of the insert was determ ined using 
digestion with the Hind III and Xba I restriction enzymes (Figure 2). 
ii. Ceruloplasmin eDNA 
A plasmid containing the human ceruloplasmin eDNA (1.2 kb) was obtained from 
Dr. R. MacGillivray (University of British Columbia). To facilitate possible riboprobe 
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Future Studies 
1.	 Validation of the aA!lllaV in identifying the estrogenicity of prototypic 
environmental estrogens. 
a. Validation of the assay to identify the estrogenicity of DDT. 
Several pesticides of chlorinated hydrocarbon have been shown to 
possess estrogenic activity. However, of the studies have demonstrated the 
estrogenicity~of o,p'-DDT both in and vitro using mouse uterus (Robison et 
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